Nucana Plc (NCNA)

$3.11

+0.13

(+4.36%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $2.85
    $3.30
    $3.11
    downward going graph

    8.36%

    Downside

    Day's Volatility :13.63%

    Upside

    5.75%

    downward going graph
  • $2.53
    $21.23
    $3.11
    downward going graph

    18.65%

    Downside

    52 Weeks Volatility :88.08%

    Upside

    85.35%

    downward going graph

Returns

PeriodNucana PlcSector (Health Care)Index (Russel 2000)
3 Months
-25.31%
6.0%
0.0%
6 Months
-59.73%
5.6%
0.0%
1 Year
-85.1%
8.5%
0.0%
3 Years
-95.09%
13.8%
-19.6%

Highlights

Market Capitalization
6.8M
Book Value
$4.51
Earnings Per Share (EPS)
-16.54
Wall Street Target Price
126.57
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-52.7%
Return On Equity TTM
-127.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-30.7M
Diluted Eps TTM
-16.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-9.01
EPS Estimate Next Year
-8.55
EPS Estimate Current Quarter
-3.49
EPS Estimate Next Quarter
-3.63

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Nucana Plc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3969.77%

Current $3.11
Target $126.57

Technicals Summary

Sell

Neutral

Buy

Nucana Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nucana Plc
Nucana Plc
0.85%
-59.73%
-85.1%
-95.09%
-98.75%
Moderna, Inc.
Moderna, Inc.
-11.58%
21.5%
-1.52%
-62.55%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.03%
12.81%
46.27%
81.23%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.55%
24.69%
62.32%
198.21%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.5%
11.69%
37.68%
150.78%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nucana Plc
Nucana Plc
NA
NA
NA
-9.01
-1.27
-0.53
NA
4.51
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nucana Plc
Nucana Plc
Buy
$6.8M
-98.75%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Nucana Plc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 144.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 198.2% return, outperforming this stock by 293.3%

Institutional Holdings

  • Sofinnova Ventures

    8.27%
  • The Carlyle Group Inc

    5.88%
  • Acadian Asset Management LLC

    1.04%
  • Renaissance Technologies Corp

    0.91%
  • Steward Partners Investment Advisory, LLC

    0.10%
  • Edmond de Rothschild Holding S.A.

    0.09%

Company Information

nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Organization
Nucana Plc
Employees
25
CEO
Mr. Hugh Stephen Griffith
Industry
Health Technology

FAQs